Endocyte Rating Increased to Outperform at Zacks (ECYT)
Endocyte (NASDAQ:ECYT) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a note issued to investors on Wednesday, Stock Ratings Network reports. The firm currently has a $14.40 price objective on the stock. Zacks‘ target price indicates a potential upside of 9.17% from the company’s current price.
Shares of Endocyte (NASDAQ:ECYT) traded down 3.18% during mid-day trading on Wednesday, hitting $12.77. 305,011 shares of the company’s stock traded hands. Endocyte has a 1-year low of $8.18 and a 1-year high of $19.00. The stock has a 50-day moving average of $10.87 and a 200-day moving average of $13.31. The company’s market cap is $461.5 million.
Separately, analysts at Piper Jaffray initiated coverage on shares of Endocyte in a research note to investors on Monday, December 2nd. They set an “overweight” rating and a $17.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. Endocyte has an average rating of “Buy” and a consensus target price of $19.24.
Endocyte, Inc (NASDAQ:ECYT) is a biopharmaceutical company.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.